RVNC
Revance Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website revance.com
- Employees(FY) 534
- ISIN US7613301099
Performance
-29.6%
1W
-20.73%
1M
-45.68%
3M
-56.36%
6M
-65.64%
YTD
-90.54%
1Y
Profile
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Investment Analysis Report: RVNC
Overview:
RVNC is a company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $488.24 million. In this report, we will conduct a detailed analysis of RVNC's financial health, earnings and revenue growth, profitability, operat...
Technical Analysis of RVNC 2024-05-10
Overview:
In analyzing the technical indicators for RVNC over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2024-05-12 04:00
3 Underappreciated Stocks That Could 10x in 10 Years(Investorplace)
- 2024-05-10 04:30
- 2024-05-10 03:04
- 2024-05-09 23:36
- 2024-05-09 22:20
- 2024-05-09 06:25
- 2024-05-09 04:06
- 2024-05-09 04:05
- 2024-05-02 16:05
- 2024-05-02 04:05
- 2024-04-12 08:00
- 2024-04-12 07:35
- 2024-04-11 20:00
- 2024-03-27 16:05
- 2024-03-27 04:05
- 2024-03-04 09:25
- 2024-03-04 06:37
Revance Announces Proposed Public Offering of Common Stock(Business Wire)
- 2024-03-03 20:25
- 2024-03-03 17:37
- 2024-03-02 08:23
- 2024-03-02 07:45
- 2024-03-01 05:47
Revance Therapeutics Full Year 2023 Earnings: Beats Expectations(Simply Wall St.)
- 2024-02-29 06:41
Q4 2023 Revance Therapeutics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-02-28 16:43
- 2024-02-28 16:05
- 2024-02-28 03:05
- 2024-02-20 19:01
- 2024-02-20 19:00
Revance to Participate in Upcoming Investor Conferences(Yahoo Finance)
- 2024-02-20 17:10
- 2024-02-01 19:00
Page 1 of 5
previousnext